Build status - In Progress

A Study to Evaluate Patients with TransthyretinMediated Amyloid Cardiomyopathy (ATTR CM)

A Study to Evaluate Patients with TransthyretinMediated Amyloid Cardiomyopathy (ATTR CM)
Recruiting
18 years - 90 years
All
Phase 3
750 participants needed
1 Location

Brief description of study

This study is for those diagnosed with transthyretin-mediated amyloid cardiomyopathy which is a disease caused by change in a protein called transthyretin (TTR). This change can either be sporadic which is known as wild-type (wtATTR-CM) or due to a mutation of the TTR gene which is hereditary (hATTR-CM). In both cases, these changes can cause the TTR to clump and build up in certain parts of your body such as your nervous system, stomach, intestines, and heart. This build up is called an amyloid deposit. Amyloid deposits can sometimes cause heart disease or neuropathy. When amyloid is deposited into the heart, it can result in a condition referred to as cardiomyopathy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cardiomyopathy
  • Age: 18 years - 90 years
  • Gender: All

Male and Female Age 18-90 Diagnosed with transthyretin-mediated amyloid cardiomyopathy

Updated on 04 Aug 2024. Study ID: 834757

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center